O-188 Phase II study of the EGFR tyrosine kinase inhibitor erlotinib (Tarceva) in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma

Authors :: Michael S. Rabin
Joan Lucca
David M. Jackman
Pasi A. Jänne
Patricia Ostler
Thomas R. Lynch
Arthur T. Skarin
Panagiotis Fidias
J. Temel
Bruce E. Johnson
Source :: Lung Cancer. 49:S62-S63
Publication Year :: 2005
Publisher :: Elsevier BV, 2005.

Subjects :: Pulmonary and Respiratory Medicine
Cancer Research
Lung
business.industry
Phases of clinical research
medicine.disease
medicine.anatomical_structure
Oncology
Carcinoma
medicine
Cancer research
In patient
Non small cell
Erlotinib
business
Egfr tyrosine kinase
medicine.drug

Full Text Access

Tools